VivaLNK’s Wearable ECG Patch Used in Study of Autonomic Function in Predicting Heart Disease

CAMPBELL, Calif., Aug. 28, 2019 /PRNewswire/ — VivaLNK, a leading provider of connected healthcare solutions, announces an agreement to provide its medical wearable ECG sensors to Emory University for a study to evaluate autonomic function in predicting coronary artery disease (CAD) and its relationship to depression and long-term outcomes. The study builds upon previous work by Emory researchers titled Circadian Autonomic Inflexibility: A Marker of Ischemic Heart Disease, which associates lower heart rate variability (HRV) with subclinical myocardial ischemia.

The VivaLNK medical wearable ECG patch contains an electrocardiography sensor and accelerometer to capture and generate multiple physiological data including ECG trace, heart rate, RR-interval, and 3-axis motion. About the size of a small bandage, the reusable and rechargeable patch weighs a mere 7.5 grams, and can be worn continuously for 72 hours at-a-time to capture and transmit data in real time.

“VivaLNK’s ECG patch is very small and comfortable to wear, which are important factors for clinical use and long-term ECG monitoring,” said Amit Shah, MD, Assistant Professor of Epidemiology at the Rollins School of Public Health at Emory University. “In addition, the software development kit makes it easy to use the patch for research and product development purposes.”

As part of the study, the device will be used to remotely monitor patients who are undergoing coronary angiography, in order to measure autonomic function. Participants will be monitored using the ECG patch for continuous 72-hour periods in a clinical and ambulatory environment, which offers a more complete picture in a natural setting. The research goal is to better understand the role of the autonomic nervous system in depression and coronary artery disease, and to develop better tools for clinical assessment.

For more information on the VivaLNK ECG Patch visit: https://www.vivalnk.com/ecg-monitor.

About VivaLNK
VivaLNK is a provider of connected healthcare solutions for wellness, patient care, and telemedicine. The company’s portfolio includes wearable medical grade devices and data analytics applications that continuously monitor the health and well-being of individuals. The company’s vision is to improve the quality and accessibility of healthcare worldwide by combining technology, data, and analytics into an integrated solution.

Media Contact:
pr@VivaLNK.com

 

View original content:http://www.prnewswire.com/news-releases/vivalnks-wearable-ecg-patch-used-in-study-of-autonomic-function-in-predicting-heart-disease-300907984.html

SOURCE VivaLNK

Staff

Recent Posts

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

12 hours ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

18 hours ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

18 hours ago

Extendicare Announces December 2025 Dividend of C$0.042 per Share

MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:…

18 hours ago

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and…

18 hours ago